The incidence of melanoma (33% for men; 23% for women) is increasing at an alarming rate with an estimated 76,380 patients being diagnosed in 2016. Accurate cutaneous melanoma staging (Stage I-Stage IV) is important for the determination of the 5 year overall survival rate and has been well characterized by the American Joint Committee on Cancer (AJCC). Microarray has been identified as a technique with higher specificity and sensitivity than FISH in identifying genomic changes in histologically equivocal lesions. Also, metastatic melanoma with BRAF activating mutations have been shown to respond to BRAF inhibitors. Gerami et al (2015) and Cirenajwis et al (2015) developed a prognostic molecular genetic signatures to predict the metastatic risk associated with melanoma from FFPE specimens (Clin Cancer Res 2015; 21:175-183; Oncotarget 2015; 6:12297-12309). For more information, please see NCCN Guidelines 1.2017 Melanoma (https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf).
GGC Offers a Comprehensive Melanoma panel (BRAFV600E and BRAF V600K mutation analysis AND prognostic regions of the genome with copy number changes) and a whole genome view of the tumor specimen. Data analysis, interpretation and reporting is performed adhering to the ACMG Standards and Guidelines for microarray analysis in neoplastic disorders (Genetics in Medicine, (2013), 15, 484�494).